Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

doi:10.1200/JCO.2014.56.2439

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2015

Pogue-Geile Katherine L, Song Nan, Jeong Jong-Hyeon, Gavin Patrick G, Kim Seong-Rim, Blackmon Nicole L, Finnigan Melanie, Rastogi Priya, Fehrenbacher Louis, Mamounas Eleftherios P, Swain Sandra M, Wickerham D Lawrence, Geyer Charles E, Costantino Joseph P, Wolmark Norman, Paik Soonmyung

Abstract excerpt

PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease-Free Survival

Share to Phosphatidylinositol 3-Kinases

Share to Randomized Controlled Trials as Topic

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 25559813
DOI: 10.1200/JCO.2014.56.2439
PMCID: PMC4397278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.PMID 25559813Read ↗

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.Semantic proximity Read ↗

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive reviewSemantic proximity Read ↗

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.Semantic proximity Read ↗

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.Semantic proximity Read ↗

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular MarkersSemantic proximity Read ↗

Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor CharacteristicsSemantic proximity Read ↗

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read ↗

Introducing Molecular Subtyping of Breast Cancer Into the Clinic?Semantic proximity Read ↗

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.Semantic proximity Read ↗

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor ExpressionSemantic proximity Read ↗

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Semantic proximity Read ↗

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.